Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

about

Pyrosequencing Analysis of Promoter Methylation in Meningioma

P2860

Q58766022-61EAB3A0-CC66-41E4-AB50-25ECE078754D

P2860

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

Item

http://www.wikidata.org/entity/Q47804454

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Clinical validation of the CE- ...... hort of glioblastoma patients.

@en

Clinical validation of the CE- ...... hort of glioblastoma patients.

@nl

type

Item

label

Clinical validation of the CE- ...... hort of glioblastoma patients.

@en

Clinical validation of the CE- ...... hort of glioblastoma patients.

@nl

prefLabel

Clinical validation of the CE- ...... hort of glioblastoma patients.

@en

Clinical validation of the CE- ...... hort of glioblastoma patients.

@nl

P1476

Clinical validation of the CE- ...... ohort of glioblastoma patients

@en

P2093

Audrey Lavenu

http://www.w3.org/2001/XMLSchema#string

Carole Ramirez

http://www.w3.org/2001/XMLSchema#string

Catherine Carpentier

http://www.w3.org/2001/XMLSchema#string

Dan Chiforeanu

http://www.w3.org/2001/XMLSchema#string

Dominique Figarella-Branger

http://www.w3.org/2001/XMLSchema#string

Elodie Vauleon

http://www.w3.org/2001/XMLSchema#string

Emmanuèle Lechapt Zalcman

http://www.w3.org/2001/XMLSchema#string

Fabienne Escande

http://www.w3.org/2001/XMLSchema#string

François Ducray

http://www.w3.org/2001/XMLSchema#string

Frédéric Fina

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions

Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma

MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study.

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of

Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.

P304

435-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/CBM-170191

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

O Chinot

Véronique Quillien

D Meyronet

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28800313

http://www.w3.org/2001/XMLSchema#string

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

about

P2860

P2860

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698